Clinical Trial

Physiological Effects of Nebulized Salbutamol in Acute Respiratory Failure Patients on HFNC

Study acronym: PENSAFE-HFNC
Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated February 7, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective physiological interventional study that assess the feasibility and safety of administering salbutamol using a vibrating mesh nebulizer during HFNC in patients with acute hypoxemic respiratory failure (AHRF). We evaluate whether this method of salbutamol delivery can reduce inspiratory effort and improve global and regional lung ventilation in AHRF patients. To achieve this, the study will record and analyze the following: esophageal pressure (Pes) curves, global and regional tidal volumes, minute ventilation, and changes in global and regional lung ventilation assessed through Electrical Impedance Tomography (EIT).
Trial Details
NCT Number NCT06815679
Lead Sponsor Università degli Studi di Ferrara
Collaborators: Aerogen
Conditions Acute Respiratory Failure, Pneumonia
Enrollment 20 participants
Start Date 2025-03-01
Primary Completion 2026-01 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2025-02-07